Cho Esther 4

What Happened
Esther Cho, SVP and General Counsel of Keros Therapeutics (KROS), disposed of 4,745 shares on February 18, 2026 in a sale that generated approximately $77,581 in proceeds. The sale was a sell-to-cover related to the vesting of restricted stock units, meaning shares were sold to satisfy tax withholding rather than an open-market discretionary divestment.

Key Details

• Transaction date: 2026-02-18 (reported on Form 4 filed 2026-02-20 — timely filing).
• Transaction type: Sale (code S) to cover tax withholding for vested RSUs (automatic, not at Cho’s discretion) — footnote F1.
• Shares sold: 4,745; weighted average price: $16.35; total proceeds: $77,581. Price range across multiple trades: $16.05–$16.65 (footnote F2).
• Other note: Filing indicates 500 shares were acquired under the issuer’s 2020 Employee Stock Purchase Plan (footnote F3).
• Shares owned after the transaction: not stated in the provided excerpt of the filing.

Context
Sell-to-cover transactions are routine tax-related sales tied to equity awards vesting and are generally not read as a strong signal of management sentiment. This was not an exercise-and-sell or a discretionary open-market sell plan; the filing states the sales were automatic to satisfy tax withholding obligations.